A 2019 study followed 42 people who had proton therapy after a mastectomy for non-metastatic breast cancer. The median follow-up was almost 3 years, and the overall survival rate was 97.2%.

Elective admissions nearly doubled over 30 years, rising from just over 1 million per quarter in 1994 (1,054,818) to almost 2 million in 2023 (1,975,508), an 87% increase. Cancellation rates increased ...